nach oben

Rheumatology International

Erschienen in:

01.04.2005 | Review Article

Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria

verfasst von: Tim Niehues, Gerd Horneff, Hartmut Michels, Michaela Sailer Höck, Lothar Schuchmann

Erschienen in: Rheumatology International | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Juvenile idiopathic arthritis (JIA) is the most common diagnosis in children and adolescents with rheumatic disorders. In many children and adolescents, JIA is successfully treated with non-steroidal anti-inflammatory drugs (NSAID) and physiotherapy. However, in a significant number of cases the disease is resistant to this therapy, and treatment with “second line” disease-modifying antirheumatic drugs (DMARDs) is required. Methotrexate (MTX) is frequently referred to as “first-choice second-line agent” for the treatment of JIA. To increase drug safety, the Working Groups for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and Pediatric Rheumatology Austria have initiated the formulation of evidence-based recommendations. Evidence is based on consensus expert meetings, a MEDLINE search with the key words “Methotrexate” and “juvenile arthritis” limited to age 0–18 years, standard textbooks and review articles, data from the central registry of the German Research Center for Rheumatic Diseases (Deutsches Rheumaforschungszentrum Berlin DRFZ), experience with MTX in adults with rheumatoid arthritis (RA), and recommendations of the German Society of Rheumatology (DGRh). Based on these data, evidence and recommendations are graded, and evidence-based recommendations for the use of MTX in children and adolescents with rheumatic disease are presented.

Cassidy JT, Petty R (2001) Textbook of pediatric rheumatology, 4th edn. WB Saunders Company, Philadelphia

Wahn V, Oppermann J, Huppertz HI, Zepp F (2001) Rheumatische Erkrankungen im Kindes- und Jugendalter. Hans Marseille Verlag, Munich

Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric Rheumatologists (2002) Health care provision in pediatric rheumatology in Germany–national rheumatologic database. J Rheumatol 29(3):622–628

Olsen NJ, Murray LM (1989) Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 32:378–385

Rosenblatt DS, Whitehead VM, Vera N, Pottier A, Dupont M, Vuchich MJ (1978) Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol Pharmacol 14:1143–1147

Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729–735CrossRef

Horneff G, Forster J, Seyberth HW, Michels H (2000) Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein, Pharmacotherapy Committee). Z Rheumatol 59:365–369CrossRef

Onel KB (2000) Advances in the medical treatment of juvenile rheumatoid arthritis. Curr Opin Pediatr 12:72–75CrossRef

Seeliger S, Niehues T, Harms E, Frosch M, Roth J (2002) Methotrexat in der Behandlung der juvenilen idiopathischen Arthritis. Monatsschr Kinderheilkd 150:452–459CrossRef

10.

Andersen PA, West SG, O’Dell JR, Via CS, Claypool RG, Kotzin BL (1985) Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103:489–496

11.

Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS (1984) A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 11:760–763

12.

Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822

13.

Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM et al (1985) Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 28:721–730

14.

Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994PubMed

15.

Feldmann W (2000) Evidence-based pediatrics, 1st edn. BC Decker, Hamilton

16.

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 13:71–72

17.

Truckenbrodt H, Hafner R (1986) Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 29:801–807

18.

Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 326:1043–1049PubMed

19.

Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I (2000) Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 43:1849–1857CrossRef

20.

Takken T, Van Der Net J, Helders PJ (2001) Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database Syst Rev 4:CD003129

21.

Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A (1999) The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 135:316–320

22.

Cassidy JT (1999) Medical management of children with juvenile rheumatoid arthritis. Drugs 58:831–850

23.

Ravelli A, Martini A (2000) Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 27:1830–1833

24.

Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27:2696–2702

25.

Padeh S, Passwell JH (1998) Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum 41:1210–1214CrossRefPubMed

26.

Ruperto N, Murray KJ, Gerloni V, Wulffraat N, De Oliveira S, Falcinin F, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Dolezalova P, Walsh J, Buoncompagni A, Garcia-Consuegra J, Ozdogan H, Saurenmann R, Joos R, Calvo I, Alpigiani LP, Machado C, Lahdenne P, Cortis E, Lepore L, Hall A, Kimura Y, Wouters C, Woo P, Martini A (2002) A randomized trial of Methotrexate in medium versus higher doses in children with juvenile idiopathic arthritis who failed on standard dose. In: EULAR Meeting Stockholm, Abstract Nr. 1384

27.

Kremer JM, Galivan J, Streckfuss A, Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29:832–835

28.

Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, Martini A (1993) Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 20:1573–1577

29.

Albertioni F, Flato B, Seideman P, Beck O, Vinje O, Peterson C, Eksborg S (1995) Methotrexate in juvenile rheumatoid arthritis. Evidence of age-dependent pharmacokinetics. Eur J Clin Pharmacol 47:507–511CrossRef

30.

Reiff A, Shaham B, Wood BP, Bernstein BH, Stanly P, Szer IS (1995) High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 13:113–118

31.

Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ (1989) Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 32:677–681PubMed

32.

Oguey D, Kolliker F, Gerber NJ, Reichen J (1992) Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 35:611–614

33.

Wallace CA (1998) The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 41:381–391

34.

Balis FM, Mirro J Jr, Reaman GH, Evans WE, McCully C, Doherty KM, Murphy RF, Jeffries S, Poplack DG (1988) Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 6:1882–1886

35.

Balis FM, Savitch JL, Bleyer WA (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43:2342–2345

36.

Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D (1993) A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20:1845–1849

37.

Furst DE, Kremer JM (1988) Methotrexate in rheumatoid arthritis. Arthritis Rheum 31:305–314

38.

Dupuis LL, Koren G, Silverman ED, Laxer RM (1995) Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 22:1570–1573

39.

Morgan SL, Baggott JE, Lee JY, Alarcon GS (1998) Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 25:441–446PubMed

40.

van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, De Boo TM, van de Putte LB (2002) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis (Oxford). Rheumatology 41:658–665CrossRef

41.

Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36–43

42.

van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524CrossRef

43.

Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S (1997) The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 24:2230–2232

44.

Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM (1990) Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J Rheumatol 17:1469–1473

45.

Singsen BH, Goldbach-Mansky R (1997) Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 23:811–840

46.

Wallace CA, Smith AL, Sherry DD (1993) Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 20:1764–1768

47.

Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC (1993) Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 20:263–267

48.

O’Dell JR (2001) Combinations of conventional disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 27:415–426

49.

Barrera P, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van de Putte LB, Van der Meer JW (1995) Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 34:747–755

50.

Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ (1995) Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 34:602–609

51.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259CrossRefPubMed

52.

Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G (2001) A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 60:410–412CrossRef

53.

Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM (1992) Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 120:468–473

54.

Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214–217CrossRef

55.

Franke J, Hafner R, Lohrs U, Truckenbrodt H (1996) Methotrexate and liver fibrosis in juvenile chronic arthritis retrospective study of 73 liver biopsies. Monatsschrift Kinderheilkunde 144:147–151

56.

Hashkes PJ, Balistreri WF, Bove KE, Ballard ET, Passo MH (1997) The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 40:2226–2234

57.

Erickson AR, Reddy V, Vogelgesang SA, West SG (1995) Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 38:1115–1119

58.

Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37:316–328

59.

McKendry RJ (1997) The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 23:939–954

60.

Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, Palmer WR, Sundy JS, St Clair EW, Alexander RW, Smith GJ, Axiotis CA (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40:1829–1837

61.

Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C (1997) Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 16:296–304

62.

Cron RQ, Sherry DD, Wallace CA (1998) Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 132:901–902

63.

Camiciottoli G, Trapani S, Castellani W, Ginanni R, Ermini M, Falcini F (1998) Effect on lung function of methotrexate and non-steroid anti-inflammatory drugs in children with juvenile rheumatoid arthritis. Rheumatol Int 18:11–16CrossRef

64.

Pelucchi A, Lomater C, Gerloni V, Foresi A, Fantini F, Marazzini L (1994) Lung function and diffusing capacity for carbon monoxide in patients with juvenile chronic arthritis: effect of disease activity and low dose methotrexate therapy. Clin Exp Rheumatol 12:675–679

65.

Schmeling H, Stephan V, Burdach S, Horneff G (2002) Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy. Z Rheumatol 61:168–172CrossRef

66.

Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 1(99):3909–3915CrossRef

67.

Rau R (1994) Treatment of chronic polyarthritis with methotrexate 1994–a review. Z Rheumatol 53:199–229

68.

Cleary AG, McDowell H, Sills JA (2002) Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkin’s lymphoma. Arch Dis Child 86:47–49CrossRef

69.

Krugmann J, Sailer-Hock M, Muller T, Gruber J, Allerberger F, Offner FA (2000) Epstein–Barr virus-associated Hodgkin’s lymphoma and Legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol 31:253–255

70.

Londino AV Jr, Blatt J, Knisely AS (1998) Hodgkin’s disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol 25:1245–1246

71.

Munro R, Porter DR, Sturrock RD (1998) Lymphadenopathy in a patient with systemic onset juvenile chronic arthritis. Ann Rheum Dis 57:513–517

72.

Padeh S, Sharon N, Schiby G, Rechavi G, Passwell JH (1997) Hodgkin’s lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 24:2035–2037

73.

Bawle EV, Conard JV, Weiss L (1998) Adult and two children with fetal methotrexate syndrome. Teratology 57:51–55

74.

Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM (1990) Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 88:589–592CrossRef

75.

Buckley LM, Bullaboy CA, Leichtman L, Marquez M (1997) Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 40:971–973

76.

Blackburn WD Jr, Alarcon GS (1989) Impotence in three rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 32:1341–1342

77.

Sussman A, Leonard JM (1980) Psoriasis, methotrexate, and oligospermia. Arch Dermatol 116:215–217CrossRef

78.

O’Dell JR (1997) Methotrexate use in rheumatoid arthritis. Rheum Dis Cl N Am 23:779–796

79.

Aherne GW, Piall E, Marks V, Mould G, White WF (1978) Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 29:1097–1099

80.

Brik R, Berkowitz D, Berant M (1998) Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis. Ann Rheum Dis 57:174–175

81.

Huang JL (1996) Methotrexate in the treatment of children with chronic arthritis–long-term observations of efficacy and safety. Br J Clin Pract 50:311–314

82.

Gottlieb BS, Keenan GF, Lu T, Ilowite NT (1997) Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 100:994–997CrossRef

83.

Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A (1995) Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 22:1574–1576

84.

Huemer M, Fodinger M, Huemer C, Sailer-Hock M, Falger J, Rettenbacher A, Bernecker M, Artacker G, Kenzian H, Lang T, Stockler-Ipsiroglu S (2003) Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. Clin Exp Rheumatol 21:249–255

85.

Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J (2004) Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis 63:206–208CrossRef

Titel: Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria
verfasst von: Tim Niehues
Gerd Horneff
Hartmut Michels
Michaela Sailer Höck
Lothar Schuchmann
Publikationsdatum: 01.04.2005
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 3/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-004-0537-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

The prevalence of symptomatic knee and distal interphalangeal joint osteoarthritis in the urban population of Antalya, Turkey

A case of idiopathic hypertrophic cranial pachymeningitis manifested only by positive rheumatoid factor and abnormal findings of the anterior falx

Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases

Development of multiple malignancies after immunosuppression in a patient with Wegener’s granulomatosis

Proposal for a sonographic classification of target joints in rheumatoid arthritis

Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin